PMID- 23344412
OWN - NLM
STAT- MEDLINE
DCOM- 20130402
LR  - 20190818
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 121
IP  - 2 Pt 2 Suppl 1
DP  - 2013 Feb
TI  - Maternal hemolysis after intravenous immunoglobulin treatment in fetal and 
      neonatal alloimmune thrombocytopenia.
PG  - 471-3
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a therapeutic agent used to 
      prevent fetal thrombocytopenia in those pregnancies identified to be at risk for 
      fetal and neonatal alloimmune thrombocytopenia. Although generally considered a 
      safe medication, hemolytic anemia is a known side effect of IVIG treatment that 
      may result in maternal medical complications. CASES: We present three cases of 
      IVIG-induced maternal anemia from separate institutions that occurred during 
      treatment for fetal and neonatal alloimmune thrombocytopenia and resolved after 
      discontinuation or alteration of therapy. None of the treated fetuses had 
      thrombocytopenia at birth. CONCLUSION: There is a potential for hemolysis when 
      prescribing IVIG. We recommend laboratory monitoring for hemolytic anemia and 
      suggest options for management including drug modification or cessation of 
      therapy.
FAU - Rink, Britton D
AU  - Rink BD
AD  - Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The 
      Ohio State University, Columbus, Ohio 43210, USA. britton.rink@osumc.edu
FAU - Gonik, Bernard
AU  - Gonik B
FAU - Chmait, Ramen H
AU  - Chmait RH
FAU - O'Shaughnessy, Richard
AU  - O'Shaughnessy R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Anemia/*chemically induced/therapy
MH  - Female
MH  - Fetal Diseases/*prevention & control
MH  - *Hemolysis
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/therapeutic use
MH  - Immunologic Factors/*adverse effects/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*chemically induced/therapy
MH  - Thrombocytopenia/*prevention & control
EDAT- 2013/02/01 06:00
MHDA- 2013/04/03 06:00
CRDT- 2013/01/25 06:00
PHST- 2013/01/25 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2013/04/03 06:00 [medline]
AID - 00006250-201302001-00019 [pii]
AID - 10.1097/aog.0b013e3182765c63 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2013 Feb;121(2 Pt 2 Suppl 1):471-3. doi: 
      10.1097/aog.0b013e3182765c63.